Clariscan makes the pictures on an MRI scanner easier to see. It does this by increasing the contrast
between the part of the body being looked at and the rest of the body. This allows doctors or
radiologists to see different areas of the body better.
For healthcare facilities, maintaining seamless medical imaging services relies heavily on consistent access to essential diagnostic imaging supplies. High-quality contrast media is fundamental to diagnostic accuracy in magnetic resonance imaging (MRI). Spectrum Medical Imaging Co. understands the critical need for dependable procurement and timely delivery of products like CLARISCAN 20ML PF 10/BX to support efficient clinical operations and deliver superior patient care. As a trusted contrast media supplier, Spectrum Medical Imaging Co. provides the reliable solutions healthcare providers need, backed by decades of industry expertise.
CLARISCAN 20 ML PF is a trusted macrocyclic gadolinium-based contrast agent containing gadoterate meglumine, formulated to deliver precise, high-resolution imaging for a broad range of contrast MRI applications. Designed for efficiency, accuracy, and safety, it supports radiology teams in improving diagnostic outcomes and streamlining workflows.
CLARISCAN 20ML PF 10/BX provides the image quality, safety profile, and convenience that today’s imaging facilities need, supporting both clinical excellence and enhanced patient care with every scan.
Choosing the right contrast agent is paramount for patient safety and diagnostic reliability in medical imaging. CLARISCAN, as a macrocyclic gadolinium-based contrast agent, is recognized for its structural stability, contributing to clinical confidence among healthcare professionals.
The macrocyclic structure of CLARISCAN contributes to low gadolinium retention compared to linear gadolinium-based contrast agents, making it a suitable option for a wide patient population. This characteristic is an important consideration for healthcare providers focused on patient safety.
As a nationwide contrast media supplier, Spectrum Medical Imaging Co. provides consistent, fast access to essential products like CLARISCAN 20ML PF 10/BX, helping healthcare facilities maintain efficient and uninterrupted medical imaging services.
With over 40 years of industry experience, Spectrum Medical Imaging Co. is a trusted partner dedicated to optimizing your radiology workflow through competitive pricing, fast delivery, and hands-on customer support.
Ensure uninterrupted access to CLARISCAN 20ML PF 10/BX with fast delivery and expert support from Spectrum Medical Imaging Co. As a trusted contrast media supplier, we offer competitive pricing, responsive service, and full technical support, including professional contrast injector repair and maintenance to keep your imaging workflow running smoothly. Contact us today to request a quote, check availability, or speak with a specialist about optimizing your medical imaging operations.
Yes, CLARISCAN is approved for use in pediatric patients aged 2 years and older. Proper dosing and monitoring help ensure safe use during an imaging exam, especially in children with underlying medical conditions or those considered high-risk patients.
While Gadolinium contrast agents are generally well tolerated, adverse reactions can include nausea, headache, dizziness, or injection site discomfort. In rare cases, allergic reactions such as rash or respiratory symptoms may occur, particularly in high-risk patients.
Like all Gadolinium-based contrast media, CLARISCAN may pose a potential risk for patients with severe renal impairment, as the agent may remain in the body for a longer period of time. Pre-screening and appropriate protocols help minimize risks, especially in vulnerable populations.
CLARISCAN 20 ML is administered via intravenous injection using standard medical imaging equipment. Its pre-filled syringe format improves efficiency and consistency, helping technologists deliver safe, accurate contrast dosing.
Patients with a history of allergic reactions should be carefully evaluated before administration. While the risk is low, Gadolinium-based contrast media may cause mild to severe hypersensitivity in rare cases. Precautionary measures are recommended for high-risk patients.
In patients with normal kidney function, Gadolinium-based contrast media like CLARISCAN are typically eliminated within a short period of time via the kidneys. However, retention may be longer in high-risk patients with renal impairment, so proper screening and post-procedure monitoring are important.
Before any imaging exam, healthcare providers should assess patient history for medical conditions, previous adverse reactions, or allergic reactions to contrast agents. This is especially important for pediatric patients and high-risk patients to ensure safe administration of Gadolinium contrast agents using appropriate medical imaging equipment.
